London Stock Exchange welcomes BioPharma Credit plc to the Premium Segment of the Main Market
BioPharma Credit, the specialist life sciences debt investor, today announces that its London listing has moved from the Specialist Fund Segment to the Premium Segment of the Main Market of London Stock Exchange. The Company’s objective in joining the Main Market is to raise the Company’s global profile, extend its potential shareholder base, and enable further scaling and a greater cadence of investment.
The move takes place just four years after BioPharma Credit first listed its shares on the Specialist Fund Segment. The Company raised US$761 million in its 30 March 2017 IPO and an additional US$624 million in three subsequent secondary offerings. Since its IPO, the Company has invested US$2,413 million in new loans to life science companies using proceeds from capital raises as well as principal repayments from loans.
BioPharma Credit’s primary objective is to generate long-term shareholder returns, predominantly in the form of sustainable income distributions from debt assets secured by approved life science products, targeting a 7 cent dividend per share per annum (approximately 7 per cent. of NAV) once substantially invested. The Company met this target in the quarter ended 30 June 2018 and has consistently paid an annualized dividend of 7 cents per share per annum plus an incremental special dividend at the end of every year since then. In total, BioPharma Credit has paid US$370 million in dividends to date.
Since IPO the Company has made 16 investments secured by a wide range of life sciences products that treat a number of serious diseases such as multiple cancers including those affecting the ovaries, brain, prostate and lymphomas, as well as rare orphan diseases such as sickle cell anemia, muscular dystrophy and Fabry disease. While the loans made by the Company are backed by approved products, a common use of proceeds for these loans is to help fund important research and development of innovative new drugs and treatments.